Connie Ha

This study shows lysosomal health influences myeloid cell states and immune responses, with Grn deficiency leading to lysosomal dysfunction and specific transcriptional changes in microglia.

This study shows chronic NLRP3 inflammasome activation leads to neutrophil entry into the brain and interactions with microglia, contributing to CNS pathology.

TN-783, a CNS-penetrant NLRP3 inhibitor, induces sustained weight loss and reverses hypothalamic inflammation in diet-induced obese mice.

This study shows that long-term anti-Aβ treatment reduces amyloid plaques and microglial activation but leaves residual plaques with persistent immune activity.

This study shows that GPR34 regulates microglia function and loss-of-function in TREM2 KO microglia rescues cholesterol metabolism, suggesting GPR34 as a therapeutic target for Alzheimer's disease.

This study compares the biodistribution of Fc-engineered molecules targeting BBB receptors with standard antibodies, showing distinct CNS and peripheral organ targeting.

DNL343 reduces neurodegeneration in mouse models by inhibiting the integrated stress response and normalizing dysregulated biomarkers, with potential clinical relevance for vanishing white matter disease.

This paper demonstrates that systemically delivered OTV, a TfR-binding molecule, effectively transports ASO across the BBB, achieving widespread and sustained knockdown of target genes in the CNS of mice and non-human primates.

This paper characterizes microglial metabolic changes in an APP knock-in mouse model of AD, finding lipid dysregulation and immunometabolic perturbations linked to fibrillar Aβ.